Tandem peptide receptor radionuclide therapy using <superscript>90</superscript> Y/ <superscript>177</superscript> Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience. - OpacWWW

Tytuł:: Tandem peptide receptor radionuclide therapy using Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience.
Autorzy:: Kunikowska J; Nuclear Medicine Department, Medical University of Warsaw, ul. Banacha 1 a, 02-097, Warsaw, Poland. .
Zemczak A; Department of Endocrinology and Neuroendocrine Tumors, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland.; Division of Endocrinology, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland.
Kołodziej M; Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine, Warsaw, Poland.
Gut P; Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland.
Łoń I; Department of Internal Medicine, Hypertension and Vascular Diseases, Medical University of Warsaw, Warsaw, Poland.
Pawlak D; Radioisotope Centre POLATOM, National Centre for Nuclear Research, -Świerk, Otwock, Poland.
Mikołajczak R; Radioisotope Centre POLATOM, National Centre for Nuclear Research, -Świerk, Otwock, Poland.
Kamiński G; Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine, Warsaw, Poland.
Ruchała M; Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland.
Kos-Kudła B; Department of Endocrinology and Neuroendocrine Tumors, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland.; Division of Endocrinology, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland.
Królicki L; Nuclear Medicine Department, Medical University of Warsaw, ul. Banacha 1 a, 02-097, Warsaw, Poland.
Źródło:: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2020 Apr; Vol. 47 (4), pp. 922-933. Date of Electronic Publication: 2020 Jan 24.
Typ publikacji:: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: Berlin : Springer-Verlag Berlin, 2002-
MeSH Terms:: Neuroendocrine Tumors*/radiotherapy
Organometallic Compounds*/adverse effects
Humans ; Octreotide/adverse effects ; Poland ; Radioisotopes ; Radiopharmaceuticals/adverse effects ; Receptors, Peptide
References:: Eur J Cancer. 2016 May;58:41-51. (PMID: 26943056)
J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S. (PMID: 15653647)
Endokrynol Pol. 2013;64(6):418-43. (PMID: 24431116)
Eur J Nucl Med Mol Imaging. 2011 Oct;38(10):1788-97. (PMID: 21553086)
J Nucl Med. 2002 May;43(5):610-6. (PMID: 11994522)
Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):223-30. (PMID: 24233003)
Clin Cancer Res. 2010 Feb 1;16(3):978-85. (PMID: 20103666)
Ann Nucl Med. 2017 Jun;31(5):347-356. (PMID: 28316066)
Semin Nucl Med. 2002 Apr;32(2):110-22. (PMID: 11965606)
N Engl J Med. 2014 Jul 17;371(3):224-33. (PMID: 25014687)
Neuroendocrinology. 2016;103(2):119-24. (PMID: 26784901)
Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):881-8. (PMID: 23443937)
Eur J Nucl Med Mol Imaging. 2004 Jul;31(7):1038-46. (PMID: 15150675)
Endokrynol Pol. 2013;64(1):13-20. (PMID: 23450442)
N Engl J Med. 2011 Feb 10;364(6):501-13. (PMID: 21306237)
Diagn Interv Radiol. 2016 May-Jun;22(3):201-6. (PMID: 27015320)
J Clin Oncol. 2008 Jun 20;26(18):3063-72. (PMID: 18565894)
J Nucl Med. 2016 May;57(5):759-64. (PMID: 26912441)
J Clin Oncol. 2008 May 1;26(13):2124-30. (PMID: 18445841)
J Nucl Med. 2005 Jan;46 Suppl 1:62S-6S. (PMID: 15653653)
J Clin Oncol. 2012 Apr 1;30(10):1100-6. (PMID: 22393097)
Am J Nucl Med Mol Imaging. 2014 Dec 15;5(1):46-55. (PMID: 25625026)
Endokrynol Pol. 2017;68(1):42-46. (PMID: 28255979)
J Nucl Med. 1994 Jan;35(1):152-6. (PMID: 8271037)
N Engl J Med. 2011 Feb 10;364(6):514-23. (PMID: 21306238)
Semin Nucl Med. 2002 Apr;32(2):123-32. (PMID: 11965607)
Endokrynol Pol. 2017;68(2):223-236. (PMID: 28540974)
Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):5-19. (PMID: 25273832)
Ann Oncol. 2012 Oct;23 Suppl 7:vii124-30. (PMID: 22997445)
Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2426-2441. (PMID: 29785514)
Eur J Nucl Med Mol Imaging. 2003 Jan;30(1):9-15. (PMID: 12483404)
N Engl J Med. 2017 Jan 12;376(2):125-135. (PMID: 28076709)
Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):417-22. (PMID: 12634971)
Endokrynol Pol. 2017;68(2):79-110. (PMID: 28597909)
Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1231-7. (PMID: 25792454)
J Clin Oncol. 2009 Oct 1;27(28):4656-63. (PMID: 19704057)
Oncotarget. 2018 Feb 15;9(24):16932-16950. (PMID: 29682195)
Contributed Indexing:: Keywords: 90Y/177Lu-DOTATATE; Neuroendocrine tumors; PRRT; Somatostatin receptor; Tandem therapy
Substance Nomenclature:: 0 (Organometallic Compounds)
0 (Radioisotopes)
0 (Radiopharmaceuticals)
0 (Receptors, Peptide)
RWM8CCW8GP (Octreotide)
Entry Date(s):: Date Created: 20200126 Date Completed: 20210514 Latest Revision: 20210514
Update Code:: 20240104
PubMed Central ID:: PMC7075861
DOI:: 10.1007/s00259-020-04690-5
PMID:: 31980909
: Czasopismo naukowe

Pełny tekst

Introduction: One of the concepts of theranostics in nuclear medicine is peptide receptor radionuclide therapy (PRRT), whereby labeled somatostatin analogs are used for imaging and treating inoperable or disseminated neuroendocrine tumors (NET).
Aim: The aim of the study was to determine the therapeutic efficacy and toxicity of tandem 90 Y / 177 Lu-DOTATATE in patients with disseminated NET in a multicenter trial.
Materials and Methods: 103 patients with NET G1/G2 treated with 90 Y/ 177 Lu-DOTATATE (1:1) with amino-acid infusion for nephroprotection were included in the study.
Results: Overall survival from the disease diagnosis (OS-D) was 127.4 months and from the time of PRRT (OS-T) was 89.5 months. Progression-free survival (PFS) was 29.9 months. An analysis based on the proliferation index revealed a statistically significant impact on PFS and OS-T (PFS G1 vs G2, 59.3 vs 24.3 months; OS-T G1 vs G2, not reached vs 79.9 months). The effect of the primary disease site was also analyzed. For pancreatic vs small bowel vs large bowel, the PFS was 30.8 vs 30.3 vs 40.6 months, the OS-T was 94 vs 61.9 vs 131.2 months and OS-D was 130.4 vs 89.2 vs not reached months, respectively. The 2-year risk of progression was 42%. The probability of 2-year and 5-year overall survival was 89% and 62%, respectively. PRRT was well tolerated by all patients. One patient (1%) developed myelodysplastic syndrome. No other grade 3 and 4 hematological or renal toxicity was observed.
Conclusions: This multicenter trial showed that tandem 90 Y/ 177 Lu-DOTATATE is highly effective and safe therapy for patients with disseminated NET.

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja

Tandem peptide receptor radionuclide therapy using 90 Y/ 177 Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience.